SEHK Growth Companies With High Insider Ownership

In This Article:

The Hong Kong market has recently experienced a downturn, with the Hang Seng Index retreating by 2.28% amid broader concerns about China's economic outlook and policy measures. Despite these challenges, opportunities remain for discerning investors, particularly in growth companies with high insider ownership. In this article, we will explore three such companies listed on the SEHK that exhibit strong growth potential and significant insider ownership—a combination that can often signal confidence in long-term prospects despite current market volatility.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

20.2%

104.1%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Adicon Holdings (SEHK:9860)

22.4%

28.3%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

73%

DPC Dash (SEHK:1405)

38.2%

91.4%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

79.3%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Beijing Airdoc Technology (SEHK:2251)

28.6%

83.9%

Ocumension Therapeutics (SEHK:1477)

23.3%

93.7%

Click here to see the full list of 53 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Meitu

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meitu, Inc. is an investment holding company that develops products for image, video, and design production to enhance industry digitalization with beauty-related solutions in China and internationally, with a market cap of HK$11.47 billion.

Operations: The company's revenue segments include an Internet Business generating CN¥2.70 billion.

Insider Ownership: 36.6%

Earnings Growth Forecast: 26.4% p.a.

Meitu, Inc. is trading significantly below its estimated fair value and has seen substantial insider buying over the past three months. The company expects annual profit growth of 26.4% and revenue growth of 17.8%, both outpacing the Hong Kong market averages. Recent earnings guidance suggests a net profit increase of at least 30% for H1 2024 compared to last year, highlighting strong financial performance despite some high-quality earnings impacted by one-off items.

SEHK:1357 Ownership Breakdown as at Jul 2024

Alibaba Health Information Technology

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Alibaba Health Information Technology Limited operates in pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of HK$53.23 billion.